ВИЧ-АССОЦИИРОВАННАЯ БОЛЕЗНЬ ПОЧЕК: ИТОГИ СОГЛАСИТЕЛЬНОЙ КОНФЕРЕНЦИИ KDIGO

ВИЧ-позитивные пациенты имеют высокий риск развития патологии почек, включая ВИЧ-ассоциированную нефропатию, неколлабирующий фокально-сегментарный гломерулосклероз, иммунокомплексное поражение почек, а также поражение почек, обусловленное длительным воздействием антиретровирусной терапии или оппортунистическими инфекциями. Клинические рекомендации по предупреждению заболеваний почек и лечению ВИЧ-позитивных пациентов в основном опираются на исследования, проведенные в общей популяции, и не до конца учитывают существующие знания в отношении уникальных патогенетических механизмов, ассоциированных с ВИЧ, и генетических факторов, способствующих развитию патологии почек в этой популяции. Мы провели встречу экспертов в нефрологии, почечной патологии, инфекционных болезнях с целью определения болезни почек в контексте ВИЧ-инфекции, уточнения роли генетических аномалий в истории заболевания, диагнозе и лечении ренальной патологии у ВИЧ-позитивных пациентов, оценки соотношения риск-польза антиретровирусной терапии и профилактики ВИЧ в отношении функции почек и разработки наилучшей тактики предупреждения и ведения болезни почек, ассоциированной с ВИЧ-инфекцией.

антиретровирусная терапия, APOL1, прогрессирование ХБП, ВИЧ, иммунокомплексная болезнь почек, подоцитопатия, патология почек

1. UNAIDS. AIDS info. Available at: http://aidsinfo.unaids.org/. Accessed July 19, 2017.

2. Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e96–e138.

3. Rosenberg AZ, Naicker S, Winkler CA, et al. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol. 2015;11:150–160.

4. D’Agati V, Appel GB. HIV infection and the kidney. J Am Soc Nephrol. 1997;8:138–152.

5. Ross MJ. Advances in the pathogenesis of HIV-associated kidney diseases. Kidney Int. 2014;86:266–274.

6. Cohen AH, Nast CC. HIV-associated nephropathy. A unique combined glomerular, tubular, and interstitial lesion. Mod Pathol. 1988;1:87–97.

7. D’Agati V, Suh JI, Carbone L, et al. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int. 1989;35:1358–1370.

8. Dijkman HB, Weening JJ, Smeets B, et al. Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells. Kidney Int. 2006;70:338–344.

9. Wyatt CM, Klotman PE, D’Agati VD. HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol. 2008;28:513–522.

10. Wearne N, Swanepoel CR, Boulle A, et al. The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations. Nephrol Dial Transplant. 2012;27:4109–4118.

11. Nadasdy T, Laszik Z, Blick KE, et al. Tubular atrophy in the end-stage kidney: a lectin and immunohistochemical study. Hum Pathol. 1994;25:22–28.

12. Ross MJ, Bruggeman LA, Wilson PD, et al. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J Am Soc Nephrol. 2001;12:2645–2651.

13. Rosenstiel PE, Gruosso T, Letourneau AM, et al. HIV-1 Vpr inhibits cytokinesis inhuman proximal tubule cells. Kidney Int. 2008;74:1049–1058.

14. Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol. 2008;28:478–486.

15. Lescure FX, Flateau C, Pacanowski J, et al. HIV-associated kidney glomerular diseases: changes with time and HAART. Nephrol Dial Transplant. 2012;27:2349–2355.

16. Mallipattu SK, Salem F, Wyatt CM. The changing epidemiology of HIV related chronic kidney disease in the era of antiretroviral therapy. Kidney Int. 2014;86:259–265.

17. Strauss J, Abitbol C, Zilleruelo G, et al. Renal disease in children with the acquired immunodeficiency syndrome. N Engl J Med. 1989;321: 625–630.

18. Nobakht E, Cohen SD, Rosenberg AZ, et al. HIVassociated immune complex kidney disease. Nat Rev Nephrol. 2016;12:291–300.

19. Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med. 1992;327:702–706.

20. Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. HIV-associated immune-mediated renal disease. Kidney Int. 1993;44:1327–1340.

21. Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with “lupus-like” features: a clinicopathologic study of 14 cases. Kidney Int. 2005;67:1381–1390.

22. Chang BG, Markowitz GS, Seshan SV, et al. Renal manifestations of concurrent systemic lupus erythematosus and HIV infection. Am J Kidney Dis. 1999;33:441–449.

23. Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South African perspective. Kidney Int. 2006;69:1885–1891.

24. Cheng JT, Anderson HL Jr, Markowitz GS, et al. Hepatitis C virus associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol. 1999;10: 1566–1574.

25. Mohan S, Herlitz LC, Tan J, et al. The changing pattern of glomerular disease in HIV and hepatitis C co-infected patients in the era of HAART. Clin Nephrol. 2013;79:285–291.

26. Stokes MB, Chawla H, Brody RI, et al. Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis. 1997;29: 514–525.

27. Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78:1171–1177.

28. Fine DM, Perazella MA, Lucas GM, et al. Kidney biopsy in HIV: beyond HIV-associated nephropathy. Am J Kidney Dis. 2008;51:504–514.

29. Parkhie SM, Fine DM, Lucas GM, et al. Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol. 2010;5:798–804.

30. Zaidan M, Lescure FX, Brocheriou I, et al. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinicopathological study. Clin J Am Soc Nephrol. 2013;8:930–938.

31. Fox C, Walker-Bone K. Evolving spectrum of HIV-associated rheumatic syndromes. Best Pract Res Clin Rheumatol. 2015;29:244–258.

32. Yoo J, Baumstein D, Kuppachi S, et al. Diffuse infiltrative lymphocytosis syndrome presenting as reversible acute kidney injury associated with Gram-negative bacterial infection in patients with newly diagnosed HIV infection. Am J Kidney Dis. 2011;57:752–755.

33. Zafrani L, Coppo P, Dettwiler S, et al. Nephropathy associated with the diffuse infiltrative lymphocytosis syndrome. Kidney Int. 2007;72: 219–224.

34. Martin-Blondel G, Debard A, Laurent C, et al. Mycobacterial-immune reconstitution inflammatory syndrome: a cause of acute interstitial nephritis during HIV infection. Nephrol Dial Transplant. 2011;26: 2403–2406.

35. Rarick MU, Espina B, Mocharnuk R, et al. Thrombotic thrombocytopenic purpura in patients with human immunodeficiency virus infection: a report of three cases and review of the literature. Am J Hematol. 1992;40:103–109.

36. del Arco A, Martinez MA, Pena JM, et al. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus infection: demonstration of p24 antigen in endothelial cells. Clin Infect Dis. 1993;17:360–363.

37. Remark R, Merghoub T, Grabe N, et al. In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Sci Immunol. 2016;1:aaf6925.

38. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–457.

39. Xu GJ, Kula T, Xu Q, et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science. 2015;348:aaa0698.

40. Kopp JB, Winkler C. HIV-associated nephropathy in African Americans. Kidney Int Suppl. 2003:S43–S49.

41. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a majoreffect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40:1175–1184.

42. Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with non diabetic end-stage renal disease in African Americans. Nat Genet. 2008;40: 1185–1192.

43. Behar DM, Rosset S, Tzur S, et al. African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic endstage kidney disease in Hispanic Americans. Hum Mol Genet. 2010;19: 1816–1827.

44. Nelson GW, Freedman BI, Bowden DW, et al. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Hum Mol Genet. 2010;19:1805–1815.

45. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329:841–845.

46. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science. 2005;309:469–472.

47. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 2003;422:83–87.

48. Cooper A, Ilboudo H, Alibu VP, et al. APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. Elife. 2017;6. pii:e25461.

49. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22:2129–2137.

50. Limou S, Nelson GW, Kopp JB, et al. APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis. 2014;21:426–433.

51. Kasembeli AN, Duarte R, Ramsay M, et al. APOL1 risk variants are strongly associated with HIV-Associated nephropathy in Black South Africans. J Am Soc Nephrol. 2015;26:2882–2890.

52. Behar DM, Kedem E, Rosset S, et al. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am J Nephrol. 2011;34:452–459.

53. Dummer PD, Limou S, Rosenberg AZ, et al. APOL1 Kidney Disease risk variants: an evolving landscape. Semin Nephrol. 2015;35:222–236.

54. Atta MG, Estrella MM, Kuperman M, et al. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int. 2012;82:338–343.

55. Ko WY, Rajan P, Gomez F, et al. Identifying Darwinian selection acting on different human APOL1 variants among diverse African populations. Am J Hum Genet. 2013;93:54–66.

56. Atta MG, Estrella MM, Skorecki KL, et al. Association of APOL1 genotype with renal histology among Black HIV-positive patients undergoing kidney biopsy. Clin J Am Soc Nephrol. 2016;11:262–270.

57. Fine DM, Wasser WG, Estrella MM, et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol. 2012;23:343–350.

58. Kopp JB, Winkler CA, Zhao X, et al. Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS clinical trial. J Am Soc Nephrol. 2015;26:1443–1448.

59. Estrella MM, Li M, Tin A, et al. The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin Infect Dis. 2015;60:646–652.

60. Estrella MM, Wyatt CM, Pearce CL, et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int. 2013;84:834–840.

61. Beckerman P, Bi-Karchin J, Park AS, et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat Med. 2017;23:429–438.

62. Nichols B, Jog P, Lee JH, et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int. 2015;87:332–342.

63. Fu Y, Zhu JY, Richman A, et al. APOL1-G1 in nephrocytes induces hypertrophy and accelerates cell death. J Am Soc Nephrol. 2017;28: 1106–1116.

64. Kruzel-Davila E, Shemer R, Ofir A, et al. APOL1-mediated cell injury involves disruption of conserved trafficking processes. J Am Soc Nephrol. 2017;28:1117–1130.

65. Ma L, Chou JW, Snipes JA, et al. APOL1 renal-risk variants induce mitochondrial dysfunction. J Am Soc Nephrol. 2017;28:1093–1105.

66. Olabisi OA, Zhang JY, VerPlank L, et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc Natl Acad Sci U S A. 2016;113:830–837.

67. Bruggeman LA, Wu Z, Luo L, et al. APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease. J Am Soc Nephrol. 2016;27:3600–3610.

68. Wan G, Zhaorigetu S, Liu Z, et al. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem. 2008;283:21540–21549.

69. Lan X, Jhaveri A, Cheng K, et al. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Renal Physiol. 2014;307:F326–F336.

70. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant. 2006;21:2809–2813.

71. Booth JW, Hamzah L, Jose S, et al. Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. Nephrol Dial Transplant. 2016;31:2099–2107.

72. Foy MC, Estrella MM, Lucas GM, et al. Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy. Clin J Am Soc Nephrol. 2013;8:1524–1532.

73. Ibrahim F, Naftalin C, Cheserem E, et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS. 2010;24:2239–2244.

74. Mocroft A, Lundgren JD, Ross M, et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015;12: e1001809.

75. Scherzer R, Gandhi M, Estrella MM, et al. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIVpositive male veterans. AIDS. 2014;28:1289–1295.

76. Woodward CL, Hall AM, Williams IG, et al. Tenofovirassociated renal and bone toxicity. HIV Med. 2009;10:482–487.

77. Hamzah L, Jose S, Booth JW, et al. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. J Infect. 2017;74: 492–500.

78. Mocroft A, Lundgren JD, Ross M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3:e23–e32.

79. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867–875.

80. Jose S, Hamzah L, Campbell LJ, et al. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis. 2014;210:363–373.

81. Post FA, Tebas P, Clarke A, et al. Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-Infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr. 2017;74:180–184.

82. Ryom L, Mocroft A, Kirk O, et al. Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. AIDS. 2017;31:1261–1270.

83. Waheed S, Attia D, Estrella MM, et al. Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series. Clin Kidney J. 2015;8:420–425.

84. Hamzah L, Booth JW, Jose S, et al. Renal tubular disease in the era of combination antiretroviral therapy. AIDS. 2015;29:1831–1836.

85. Chughlay MF, Njuguna C, Cohen K, et al. Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis. AIDS. 2015;29:503–504.

86. Doco-Lecompte T, Garrec A, Thomas L, et al. Lopinavirritonavir (Kaletra) and lithiasis: seven cases. AIDS. 2004;18:705–706.

87. Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis. 2012;55:1262–1269.

88. Schmid S, Opravil M, Moddel M, et al. Acute interstitial nephritis of HIV positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch. 2007;450: 665–670.

89. Shafi T, Choi MJ, Racusen LC, et al. Ritonavir-induced acute kidney injury: kidney biopsy findings and review of literature. Clin Nephrol. 2011;75(Suppl 1):60–64.

90. Jose S, Nelson M, Phillips A, et al. Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. AIDS. 2017;31:485–492.

91. Cahn P, Andrade-Villanueva J, Arribas JR, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014;14:572–580.

92. Perez-Molina JA, Rubio R, Rivero A, et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, openlabel, non-inferiority trial. Lancet Infect Dis. 2015;15:775–784.

93. Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviralnaive adults infected with HIV-1: 96 week results from the NEAT001/ ANRS143 randomised non-inferiority trial. Lancet. 2014;384: 1942–1951.

94. Abraham AG, Althoff KN, Jing Y, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015;60:941–949.

95. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–272.

96. Wong C, Gange SJ, Buchacz K, et al. First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIVinfected adults, 2000-2013. Clin Infect Dis. 2017;64:459–467.

97. Lucas GM, Jing Y, Sulkowski M, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013;208: 1240–1249.

98. Mocroft A, Neuhaus J, Peters L, et al. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One. 2012;7:e40245.

99. Jha V, Prasad N. CKD and infectious diseases in Asia Pacific: challenges and opportunities. Am J Kidney Dis. 2016;68:148–160.

100. Shen TC, Huang KY, Chao CH, et al. The risk of chronic kidney disease in tuberculosis: a population-based cohort study. QJM. 2015;108:397–403.

101. Wen YK, Chen ML. Crescentic glomerulonephritis associated with miliary tuberculosis. Clin Nephrol. 2009;71:310–313.

102. Choi AI, Li Y, Parikh C, et al. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int. 2010;78:478–485.

103. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3: 1–150.

104. Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis. 2010;56: 872–882.

105. Shlipak MG, Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369: 932–943.

106. Inker LA, Wyatt C, Creamer R, et al. Performance of creatinine and cystatin C GFR estimating equations in an HIVpositive population on antiretrovirals. J Acquir Immune Defic Syndr. 2012;61:302–309.

107. Lucas GM, Cozzi-Lepri A, Wyatt CM, et al. Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV Med. 2014;15: 116–123.

108. Seape T, Gounden V, van Deventer HE, et al. Cystatin C- and creatininebased equations in the assessment of renal function in HIV-positive patients prior to commencing highly active antiretroviral therapy. Ann Clin Biochem. 2016;53:58–66.

109. Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014;28:621–632.

110. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–1421.

111. Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am. 2005;89:457–473.

112. Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652–660.

113. Yombi JC, Jones R, Pozniak A, et al. Monitoring of kidney function in HIV-positive patients. HIV Med. 2015;16:457–467.

114. Yahaya I, Uthman AO, Uthman MM. Interventions for HIV-associated nephropathy. Cochrane Database Syst Rev. 2009:CD007183.

115. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva, Switzerland; 2014.

116. Kidney Disease: Impproving global Outcomes (KDIGO) Blood Pressure Working Group. KDIGO Clinical Practice Guidelines for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Intl Suppl. 2012;2: 337–414.

117. Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103–2116.

118. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland; 2015.

119. Nahid P, Dorman SE, Alipanah N, et al. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63: 853–867.

120. Pol S, Jadoul M, Vallet-Pichard A. An update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO Guidelines. Nephrol Dial Transplant. 2017;32:32–35.

121. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283.

122. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol. 2002;13:1889–1893.

123. Ahuja TS, Collinge N, Grady J, et al. Is dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy? Am J Kidney Dis. 2003;41:1060–1064.

124. Soleymanian T, Raman S, Shannaq FN, et al. Survival and morbidity of HIV patients on hemodialysis and peritoneal dialysis: one center’s experience and review of the literature. Int Urol Nephrol. 2006;38: 331–338.

125. Mitchell D, Krishnasami Z, Young CJ, et al. Arteriovenous access outcomes in haemodialysis patients with HIV infection. Nephrol Dial Transplant. 2007;22:465–470.

126. Wreghitt TG. Blood-borne virus infections in dialysis units–a review. Rev Med Virol. 1999;9:101–109.

127. Centers for Disease Control and Prevention. Current trends recommendations for providing dialysis treatment to patients infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. MMWR. 1986;35:376–378, 383.

128. Centers for Disease Control and Prevention. Preventing infections in dialysis setting guideline. Available at: https://www.cdc.gov/infectioncontrol/guidelines/dialysis/index.html. Accessed July 19, 2017.

129. Ndlovu KC, Sibanda W, Assounga A. Peritonitis outcomes in patients with HIV and end-stage renal failure on peritoneal dialysis: a prospective cohort study. BMC Nephrol. 2017;18:48.

130. Farzadegan H, Ford D, Malan M, et al. HIV-1 survival kinetics in peritoneal dialysis effluent. Kidney Int. 1996;50:1659–1662.

131. Ndlovu KC, Sibanda W, Assounga A. Detection of human immunodeficiency virus-1 ribonucleic acid in the peritoneal effluent of renal failure patients on highly active antiretroviral therapy. Nephrol Dial Transplant. 2017;32:714–721.

132. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363:2004–2014.

133. Locke JE, Gustafson S, Mehta S, et al. Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg. 2017;265:604–608.

134. Gathogo EN, Hamzah L, Hilton R, et al. Kidney transplantation in HIV-positive adults: the UK experience. Int J STD AIDS. 2014;25:57–66.

135. Gathogo EN, Shah S, Post FA. Kidney transplant outcomes in HIV serodiscordant recipient pairs. AIDS. 2017;31:1199–1201.

136. Locke JE, Mehta S, Sawinski D, et al. Access to kidney transplantation among HIV-infected waitlist candidates. Clin J Am Soc Nephrol. 2017;12: 467–475.

137. Muller E, Barday Z, Mendelson M, et al. HIV-positive-to-HIV-positive kidney transplantation–results at 3 to 5 years. N Engl J Med. 2015;372: 613–620.

138. Waheed S, Sakr A, Chheda ND, et al. Outcomes of re nal transplantation in HIV-1 associated nephropathy. PLoS One. 2015;10:e0129702.

139. McLean FE, Gathogo E, Goodall D, et al. Alemtuzumab induction therapy in HIV-positive renal transplant recipients. AIDS. 2017;31:1047–1048.

140. Gathogo E, Harber M, Bhagani S, et al. Impact of tacrolimus compared with cyclosporin on the incidence of acute allograft rejection in human immunodeficiency virus-positive kidney transplant recipients. Transplantation. 2016;100:871–878.

141. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.

142. Karuthu S, Blumberg EA. Common infections in kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7:2058–2070.

143. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;109:S1–S99.

144. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.

145. Sawinski D, Shelton BA, Mehta S, et al. Impact of protease inhibitor based anti-retroviral therapy on outcomes for HIVю kidney transplant recipients. Am J Transplant. 2017;17:3114–3122.

146. Canaud G, Dejucq-Rainsford N, Avettand-Fenoel V, et al. The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol. 2014;25:407–419.

147. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Centers (Collaborative U01), RFADK- 16–025. In: Department of Health and Human Services N, ed. Available at: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-025.html. Accessed June 19, 2017.

148. Muller E, Barday Z, Kahn D. HIV-positive-to-HIV-positive kidney transplantation. N Engl J Med. 2015;372:2070–2071.

149. Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med. 2010;362:2336–2337.

150. Organ procurement and transplantation: implementation of the HIV Organ Policy Equity Act. Final rule. Fed Regist. 2015;80:26464–26467.

151. Boyarsky BJ, Segev DL. From bench to bill: how a transplant nuance became 1 of only 57 laws passed in 2013. Ann Surg. 2016;263:430–433.

152. Papeta N, Kiryluk K, Patel A, et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol. 2011;22: 1991–1996.

153. Purswani MU, Patel K, Winkler CA, et al. Brief report: APOL1 renal risk variants are associated with chronic kidney disease in children and youth with perinatal HIV infection. J Acquir Immune Defic Syndr. 2016;73:63–68.

154. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385: 2606–2615.

155. Abboud O, Becker G, Bellorin-Font E, et al. KDIGO clinical practice guidelines on hepatitis C in chronic kidney disease acknowledged by ISN. Nat Clin Pract Nephrol. 2008;4:648–649.

156. Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories. J Viral Hepat. 2017;24:442–453.

157. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End- Stage Renal Disease. Gastroenterology. 2016;150:1590–1598.

158. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386: 1537–1545.

159. Bhamidimarri KR, Czul F, Peyton A, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63:763–765.

160. Dumortier J, Bailly F, Pageaux GP, et al. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. Nephrol Dial Transplant. 2017;32:2065–2071.

161. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807–816.

162. Kim PS, Woods C, Georgoff P, et al. A1C underestimates glycemia in HIV infection. Diabetes Care. 2009;32:1591–1593.

163. Slama L, Palella FJ Jr, Abraham AG, et al. Inaccuracy of haemoglobin A1c among HIV-infected men: effects of CD4 cell count, antiretroviral therapies and haematological parameters. J Antimicrob Chemother. 2014;69:3360–3367.

164. Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377: 1448–1455.

165. AASLD/IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Patients with renal impairment. Available at: https://www.hcvguidelines.org/uniquepopulations/renal-impairment.